probiotics (Guarner, et al., 2012) . Because of the great variation among bacterial species and strains used in the different human studies, it has so far been very difficult to clarify specific benefits for specific bacterial strains. Different bacterial strains have been approved by The European Union for use as feed additives for different domestic animal species (EU register of feed additives, 2017). To date, four bacterial strains have been examined by the European Food Safety Authority (EFSA) for their safety and efficacy as probiotics or feed additives in dogs. This includes two Enterococcus faecium strains (E. faecium NCIMB 10415 E1705, E. faecium NCIMB 10415 E1707), Lactobacillus acidophilus DSM 13241 25 and Bifidobacterium sp. animalis. (Schmitz & Suchodolski, 2016) . Only E. faecium NCIMB 10415 E1705 and E. faecium NCIMB 10415 E1707 have been approved for use as feed additives in dogs.
Gastrointestinal diseases are common in dogs (Kozak, Bilek, Fialcovicova, Neuschl, & Stratilova, 2001) , (Hubbard, Skelly, McKelvie, & Wood, 2007) . A high percentage of dogs presenting with diarrhea in the UK are treated with probiotics either as the only or as a supplemental treatment (German, Halladay, & Noble, 2010) . Considering the claimed benefits of using probiotics in treating human gastrointestinal diseases and the increased focus on possible benefits of probiotics in veterinary medicine, the objective of this analysis is to look for evidence based medicine concerning the clinical effects, when probiotics are used in the treatment or prevention of gastrointestinal diseases in dogs. All studies using probiotics (containing different bacterial species or strains) to treat or prevent gastrointestinal diseases in dogs, will be included in the analysis.
The canine IBD activity index" (CIBDAI) have been used to monitor dogs with inflammatory bowel disease (Jergens, et al., 2003) . Clinical parameters regarding attitude/activity, appetite, vomiting, stool consistency (+/-blood & mucus), stool frequency and weight loss, was evaluated in this index. In 2008 another clinical scoring index (The canine chronic enteropathy clinical activity index -CCECAI) was defined and valuable for all dogs with chronic intestinal disease after exclusion of endoparasites and enteropathogens (Allenspach, Wieland, Gröne, & Gaschen, 2007) . On top of the clinical parameter evaluated by the CIBDAI, albumin level, ascites/peripheral edema and owners subjectively assessment of pruritus were included into The CCECAI. Clinical parameters used to evaluate dogs with acute gastrointestinal diseases often include the same parameters with less attention to weight loss, albumin level, ascites/peripheral edema and pruritus. All clinical parameters are evaluated in relation to a time frame. These parameters are very much alike the parameters used in the human studies, and therefore will be used in this analysis to evaluate benefits of probiotics in dogs with gastrointestinal disease.
The following research question have been formulated: "What is the evidence concerning clinical effects, when probiotics are used in treatment or prevention of gastrointestinal diseases in dogs". Toolkit 1 and 2(http://knowledge.rcvs.org.uk/evidence-based-veterinary-medicine/ebvm-toolkit/) has been used to formulate the research question (Table 1 ).
The 0-hypothesis of this study is: "No clinical benefits are seen when probiotics are used as the only or supplemental treatment of dogs with or likely to get gastrointestinal diseases". 
